Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
03 Outubro 2023 - 5:43PM
Business Wire
Final decision follows multiple previous court
rulings in favor of Natera and upholds invalidation of CareDx
patents
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
(cfDNA) testing, today announced that the United States Supreme
Court denied CareDx, Inc.’s (NASDAQ: CDNA) petition for certiorari
concerning a patent infringement lawsuit brought by CareDx against
Natera. This decision confirms the invalidity of the patents
asserted against Natera and follows three previous rulings on the
matter:
- A September 2021 decision by the United States District Court
for the District of Delaware, affirming that all three CareDx
patents asserted against Natera were invalid for claiming
patent-ineligible subject matter.
- A June 2022 decision by the United States Court of Appeals for
the Federal Circuit, affirming the Delaware Court’s decision.
- A December 2022 denial of rehearing by the United States Court
of Appeals for the Federal Circuit.
This final decision by the Supreme Court rejects the request by
CareDx to litigate this matter once again and effectively
terminates any existing claims brought by CareDx against Natera
concerning these patents.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 150 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
developments in matters under dispute or litigation, the scope of
protection we establish and maintain for, and developments or
disputes concerning, our intellectual property or other proprietary
rights, and our expectations of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in “Risk
Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003906151/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024